

POLICY NAME	Vivjoa (oteseconazole)	POLICY #	3164P
--------------------	------------------------	-----------------	-------

Criteria

Recurrent Vulvovaginal Candidiasis (RVVC)

- ☐ Documented diagnosis of recurrent vulvovaginal candidiasis
 - Recurrent defined as ≥ 3 symptomatic episodes of VVC within the previous 12 months
 - Acute episodes must be confirmed VVC as evidenced by positive KOH test
- ☐ Age 12 years or older and biologically female
- ☐ Patient is post-menopausal or not of reproductive potential due to some other female infertility
- ☐ Patient has experienced a recurrence during or following 6 months of oral fluconazole maintenance treatment or has a contraindication to fluconazole

Exclusion Criteria – Any of the following prevents coverage

- ☐ Vivjoa will not be covered in combination with Brexafemme for the prevention of RVVC